Rapport Therapeutics, Inc. RAPP

RAPP Company Overview

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for neurological disorders with significant unmet medical need. The company operates within the biopharmaceutical and neuroscience drug development industries, with a scientific emphasis on targeting receptor-associated protein complexes in the brain to achieve greater therapeutic selectivity. Rapport Therapeutics does not have any approved products and does not generate commercial revenue as of its most recent public filings.

The company’s primary value driver is its pipeline of small‑molecule therapeutics designed to modulate specific neural signaling pathways implicated in disorders such as epilepsy and other central nervous system conditions. Rapport Therapeutics is positioned around a differentiated platform that seeks to improve efficacy and safety compared to broadly acting neurological drugs. The company was founded in 2020 and launched with backing from Third Rock Ventures, subsequently advancing its lead program into clinical development and completing an initial public offering on the Nasdaq under the ticker RAPP.